Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus versus hydroxychloroquine/placebo with clobetasol for lichen planopilaris
IRCT20260509069309N1Phase 2Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sirolimus, hydroxychloroquine, clobetasol and Placebo-COD Research Private Ltd in lichen planopilaris (LPP) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Lichen Planopilaris Activity Index at Month 9, Dermatology Life Quality Index at Month 9 and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
sirolimushydroxychloroquineclobetasolPlacebo-COD Research Private Ltd
03
Conditions
lichen planopilaris (LPP)
Beyond the preview
Go deeper on IRCT20260509069309N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260509069309N1.